Author

J.-F. Rossignol

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

A. Riccio· 2 shared A. Rossi· 2 shared M. G. Santoro· 2 shared S. Piacentini· 2 shared S. Santopolo· 2 shared A. A. Wilson· 1 shared A. Cupic· 1 shared A. E. Goldfeld· 1 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Riccio

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Antiviral effect of thiazolides relies on mitochondrial mild uncoupling

N. Hammad, C. Ransy, B. Pinson, J. Talmasson, C. Brechot, F. Bouillaud, J.-F. Rossignol

The paper investigates how thiazolides, specifically Nitazoxanide, reduce viral release by mildly uncoupling mitochondrial oxidative phosphorylation, showing this effect is significant even with modest deviations from normal.

bioRxiv · Sep 16, 2022 · PreprintBiochemistry

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein

S. Piacentini, A. Riccio, S. Santopolo, S. Pauciullo, S. La Frazia, A. Rossi, J.-F. Rossignol, M. G. Santoro

The paper shows nitazoxanide inhibits seasonal coronaviruses by interfering with spike glycoprotein maturation, not affecting viral entry.

bioRxiv · Jul 13, 2022 · PreprintMicrobiology

The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters

L. Miorin, C. E. Mire, S. Ranjbar, A. J. Hume, J. Huang, N. A. Crossland, K. M. White, M. Laporte, T. Kehrer, V. Haridas, E. Moreno, A. Nambu, S. Jangra, A. Cupic, M. Dejosez, , A. E. Goldfeld

The paper shows that nitazoxanide inhibits SARS-CoV-2 replication and pathogenesis in human and hamster models, and synergizes with remdesivir against multiple variants.

bioRxiv · Feb 8, 2022 · PreprintImmunology

Mechanism of Antiviral Activity of Nitazoxanide against the Influenza Virus: Effect of Tizoxanide on AdenosineTriphosphate in Influenza-virus Infected Madin Darby Canine Kidney Cells

J.-F. Rossignol, C. v. Baalen, A. Tijsma

This study evaluates how tizoxanide affects ATP levels in influenza-virus infected MDCK cells and links this effect to antiviral activity.

bioRxiv · Jul 30, 2021 · PreprintMicrobiology

Impairment of SARS-CoV-2 spike-glycoprotein maturation and fusion-activity by nitazoxanide: an effect independent of spike variants emergence

A. Riccio, S. Santopolo, A. Rossi, S. Piacentini, J.-F. Rossignol, M. G. Santoro

This study shows nitazoxanide impairs SARS-CoV-2 spike maturation and fusion activity, effective against multiple variants including Delta.

bioRxiv · Apr 12, 2021Microbiology